Gentium Shares Falling as Defibrotide Faces Delay Again

Sheridan, Cormac
February 2013
BioWorld International;2/27/2013, Vol. 18 Issue 9, p1
The article reports on the 20% decline of shares in Gentium SpA as the approval process for defibrotide, which is a drug treatment for hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant, faces delay. Salvatore Calabrese, chief financial officer at Gentium, says that they are profitable in selling the drug on a named-patient basis. It mentions that the company develops the drug for VOD under orphan drug rules.


Related Articles

  • Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Nagler, A; Labopin, M; Berger, R; Bunjes, D; Campos, A; Socié, G; Kröger, N; Goker, H; Yakoub-Agha, I; Shimoni, A; Mohty, M; Rocha, V // Bone Marrow Transplantation;May2014, Vol. 49 Issue 5, p628 

    I.v. BU is frequently used in the conditioning regimen prior to allogeneic hematopoietic SCT (allo-HSCT); however, overall outcomes, incidence of hepatic sinusoidal obstructive syndrome (SOS) and its risk factors are not well known. With this aim, we performed a study on 257 AML adult...

  • MTHFR C677T/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome. Efrati, E; Zuckerman, T; Ben-Ami, E; Krivoy, N // Bone Marrow Transplantation;May2014, Vol. 49 Issue 5, p726 

    The article offers information on a study which examines the risk factor of methylenetetrahydrofolate reductase (MTFFR) C677T/A1298C for liver sinusoidal obstruction syndrome on patients who underwent hematopoietic stem cell transplantation (HSCT). The study involved 62 adult patients who...

  • Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA? Yoon, J-H; Min, W-S; Kim, H-Je; Kim, J-H; Shin, S-H; Yahng, S-A; Lee, S-E; Cho, B-S; Eom, K-S; Kim, Y-J; Lee, S; Min, C-K; Cho, S-G; Kim, D-W; Lee, J-W; Park, C-W // Bone Marrow Transplantation;Dec2013, Vol. 48 Issue 12, p1562 

    Hepatic veno-occlusive disease (VOD) remains one of the most severe complications of hematopoietic SCT (HSCT). Anticoagulation and thrombolytic therapies using tissue-plasminogen activator (t-PA) have been used, but are reported to be ineffective and are associated with significant bleeding...

  • Jazz paying $1B for Gentium; gains rights to defibrotide. Sheridan, Cormac // BioWorld Today;12/23/2013, Vol. 24 Issue 245, p1 

    The article reports on the acquisition of 57 percent of the shares of Gentium SpA by Jazz Pharmaceuticals plc. It talks about the Defitelio (defibrotide) drug of Gentium which has been approved by the European Union (EU) and will be launched at the European Society for Blood and Bone Marrow...

  • EMBT calls for innovation through cooperation. Lyon, Sue // British Journal of Hospital Medicine (17508460);May2014, Vol. 75 Issue 5, p251 

    The article discusses the launch of the drug defibrotide for severe hepatic veno-occlusive disease after haematopoietic stem cell transplantation, which is regarded as a model for cooperation of investigators, international scientific societies, and industry. Topics include the view of European...

  • Iron Toxicity in Hematopoietic Stem Cell Transplantation: Strike while the Iron Is Labile. Pullarkat, Vinod // Acta Haematologica;May2014, Vol. 131 Issue 4, p220 

    No abstract available

  • Changes in taste among pediatric patients with cancer and hematopoietic stem cell transplantation recipients. Loves, Robyn; Plenert, Erin; Tomlinson, Vivian; Palmert, Sasha; Green, Gloria; Schechter, Tal; Tomlinson, Deborah; Vettese, Emily; Zupanec, Sue; Dupuis, L. Lee; Sung, Lillian // Quality of Life Research;Nov2019, Vol. 28 Issue 11, p2941 

    Purpose: Changes in taste is a common bothersome symptom in children receiving cancer treatments. However, little is known about how pediatric cancer patients experience this symptom. The objective was to describe how children receiving cancer treatments experience taste alterations and the...

  • Gentium Announces NDA Submission for Defibrotide.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p2 

    The article reports on a new drug application (NDA) submitted by Gentium SpA to the U.S. Food and Drug Administration (FDA) for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). The drug has allegedly been...

  • Gentium Shares Falling as Defibrotide Faces Delay Again. Sheridan, Cormac // BioWorld Today;2/25/2013, Vol. 24 Issue 36, p1 

    The article reports that share prices for Gentium SpA has fallen 20 percent due to the delayed approval of the drug defibrotide. The drug is developed for the treatment and prevention of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant. Preliminary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics